In short
Dacarbazine (DTIC) is a chemotherapy drug that has been studied extensively in clinical trials for the treatment of various cancers, particularly melanoma. This article summarizes key information about clinical trials investigating dacarbazine alone or in combination with other therapies for cancer patients.
At a glance
- Main cancer type studied
- Melanoma (skin cancer)
- Other cancers studied
- Soft tissue sarcomas, leiomyosarcoma
- Common dosing
- 800-1000 mg/m2 intravenously every 3-4 weeks
- Combination approaches
- With targeted therapies (e.g. sorafenib), immunotherapies, other chemotherapies
- Key outcome measures
- Progression-free survival, overall survival, tumor response rate
- Common side effects
- Nausea, vomiting, fatigue, lowered blood cell counts
- Trial phases
- Phase 1, 2, and 3 studies represented
What is DACARBAZINE?
DACARBAZINE, also known as DTIC or DTIC-Dome, is a chemotherapy drug used to treat various types of cancer. It belongs to a class of medications called alkylating agents, which work by damaging the DNA of cancer cells, preventing them from dividing and growing. DACARBAZINE has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain cancers, particularly melanoma (a type of skin cancer).
How DACARBAZINE Works
DACARBAZINE is designed to cause cancer cell death by creating breaks in the DNA within the nucleus of cancer cells. By damaging the genetic material of cancer cells, DACARBAZINE interferes with their ability to reproduce and spread. This mechanism of action helps to slow down or stop the growth of tumors in patients with certain types of cancer.
Conditions Treated with DACARBAZINE
DACARBAZINE is primarily used to treat the following conditions:
- Metastatic Melanoma: This is an advanced form of skin cancer that has spread to other parts of the body. DACARBAZINE is often used as a standard treatment for patients with metastatic melanoma.
- Hodgkin Lymphoma: DACARBAZINE may be used as part of a combination therapy for patients with Hodgkin lymphoma, a cancer of the lymphatic system.
- Soft Tissue Sarcoma: Some clinical trials have explored the use of DACARBAZINE in treating certain types of soft tissue sarcomas, which are cancers that develop in the body's soft tissues.
How DACARBAZINE is Administered
DACARBAZINE is typically administered intravenously (through a vein) in a hospital or clinic setting. The dosage and frequency of treatment can vary depending on the specific condition being treated and the patient's individual factors. Some common administration methods include:
- A dose of 850 mg/m² given by intravenous infusion over 60 minutes, repeated every 3 weeks.
- A dose of 1000 mg/m² given intravenously every 3 weeks.
- In some combination therapies, DACARBAZINE may be given at a dose of 375 mg/m² on days 1 and 15 of each 28-day cycle.
It's important to note that the exact dosing schedule will be determined by your healthcare provider based on your specific situation.
Potential Side Effects
Like all chemotherapy drugs, DACARBAZINE can cause side effects. Some of the most common side effects include:
- Nausea and vomiting: This is a very common side effect, but modern anti-nausea medications can help manage this.
- Bone marrow suppression: This can lead to a decrease in white blood cells (increasing the risk of infection), red blood cells (causing anemia), and platelets (increasing the risk of bleeding).
- Fatigue: Many patients experience tiredness during treatment.
- Loss of appetite
- Skin reactions: Some patients may experience rashes or increased sensitivity to sunlight.
Your healthcare team will monitor you closely for these and other potential side effects and can provide treatments to help manage them.
Ongoing Research and Combination Therapies
Researchers are continually studying DACARBAZINE to find ways to improve its effectiveness and reduce side effects. Some areas of ongoing research include:
- Combination therapies: DACARBAZINE is being studied in combination with other drugs to potentially enhance its effectiveness. For example:
- Combination with Sorafenib for soft tissue sarcomas.
- Combination with immunotherapy drugs for melanoma.
- Combination with Brentuximab Vedotin and other chemotherapy drugs for Hodgkin Lymphoma.
- Comparing DACARBAZINE to newer treatments: Studies are comparing the effectiveness of DACARBAZINE to newer targeted therapies and immunotherapies for melanoma.
- Improving side effect management: Researchers are exploring ways to better manage the side effects of DACARBAZINE, such as using growth factors to reduce the risk of low blood cell counts.
These ongoing studies aim to improve outcomes for patients and potentially expand the use of DACARBAZINE in cancer treatment.